{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T05:13:41Z","timestamp":1772169221869,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T00:00:00Z","timestamp":1589587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s00277-020-04025-2","type":"journal-article","created":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T09:03:17Z","timestamp":1589619797000},"page":"1595-1604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Progression of disease within 2\u00a0years (POD24) is a clinically relevant endpoint to identify high-risk follicular lymphoma patients in real life"],"prefix":"10.1007","volume":"99","author":[{"given":"Clara","family":"Sortais","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Lok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benoit","family":"Tessoulin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Gastinne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viviane","family":"Dubruille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Blin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C\u00e9line","family":"Bossard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Peterlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Guillaume","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amandine","family":"Le Bourgeois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Leux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Le Gouill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,5,16]]},"reference":[{"issue":"11","key":"4025_CR1","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood.V89.11.3909","volume":"89","author":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma","year":"1997","unstructured":"A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin\u2019s lymphoma (1997) The Non-Hodgkin\u2019s Lymphoma Classification Project. Blood 89(11):3909\u20133918","journal-title":"Blood"},{"issue":"1","key":"4025_CR2","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1200\/JCO.1995.13.1.140","volume":"13","author":"PW Johnson","year":"1995","unstructured":"Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J, Matthews J, Norton AJ, Amess JA, Lister TA (1995) Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 13(1):140\u2013147","journal-title":"J Clin Oncol"},{"issue":"23","key":"4025_CR3","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","volume":"33","author":"C Casulo","year":"2015","unstructured":"Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR et al (2015) Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National LymphoCare Study. J Clin Oncol 33(23):2516\u20132522","journal-title":"J Clin Oncol"},{"key":"4025_CR4","doi-asserted-by":"crossref","unstructured":"Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R et al (2016) The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood (20):127, 2375\u20132190","DOI":"10.1182\/blood-2016-01-643569"},{"key":"4025_CR5","doi-asserted-by":"crossref","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","DOI":"10.1200\/JCO.2006.09.2403"},{"issue":"6","key":"4025_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET et al (1982) Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol 5(6):649\u2013655","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"4025_CR7","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","volume":"104","author":"P Solal-Celigny","year":"2004","unstructured":"Solal-Celigny P (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258\u20131265","journal-title":"Blood"},{"issue":"27","key":"4025_CR8","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","volume":"27","author":"M Federico","year":"2009","unstructured":"Federico M, Bellei M, Marcheselli L, Luminari S, Lopez-Guillermo A, Vitolo U et al (2009) Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 27(27):4555\u20134562","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"4025_CR9","first-page":"486","volume":"130","author":"GA Salles","year":"2017","unstructured":"Salles GA, Seymour JF, Feugier P, Offner F, Lopez-Guillermo A, Belada D et al (2017) Long term follow-up of the PRIMA study: half of patients receiving rituximab maintenance remain progression free at 10 Years. Blood 130(Suppl 1):486\u2013486","journal-title":"Blood"},{"issue":"2","key":"4025_CR10","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1200\/JCO.18.00400","volume":"37","author":"C Sarkozy","year":"2019","unstructured":"Sarkozy C, Maurer MJ, Link BK, Ghesquieres H, Nicolas E, Thompson CA et al (2019) Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US cohorts. J Clin Oncol 37(2):144\u2013152","journal-title":"J Clin Oncol"},{"issue":"10","key":"4025_CR11","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1056\/NEJMoa1805104","volume":"379","author":"F Morschhauser","year":"2018","unstructured":"Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML et al (2018) Rituximab plus lenalidomide in advanced untreated follicular lymphoma. N Engl J Med 379(10):934\u2013947","journal-title":"N Engl J Med"},{"issue":"14","key":"4025_CR12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","volume":"377","author":"R Marcus","year":"2017","unstructured":"Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C et al (2017) Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med 377(14):1331\u20131344","journal-title":"N Engl J Med"},{"key":"4025_CR13","doi-asserted-by":"crossref","unstructured":"Bachy E, Seymour JF, Feugier P, Offner F, L\u00f3pez-Guillermo A, Belada D, et al. (2019) Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma: long-term results of the PRIMA study. J Clin Oncol JCO.19.01073","DOI":"10.1200\/JCO.19.01073"},{"key":"4025_CR14","doi-asserted-by":"crossref","unstructured":"Manna M, Lee-Ying R, Davies G, Stewart C, Oh DH, Peters A, et al (2018) Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: a multi-center retrospective analysis of consecutively treated patients in the real world. Leuk Lymphoma 1\u20139","DOI":"10.1080\/10428194.2018.1473576"},{"issue":"33","key":"4025_CR15","doi-asserted-by":"publisher","first-page":"3315","DOI":"10.1200\/JCO.18.00262","volume":"36","author":"S Lockmer","year":"2018","unstructured":"Lockmer S, \u00d8stenstad B, Hagberg H, Holte H, Johansson A-S, Wahlin BE et al (2018) Chemotherapy-free initial treatment of advanced indolent lymphoma has durable effect with low toxicity: results from two nordic lymphoma group trials with more than 10 years of follow-up. J Clin Oncol 36(33):3315\u20133323","journal-title":"J Clin Oncol"},{"issue":"11","key":"4025_CR16","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ajh.24492","volume":"91","author":"MJ Maurer","year":"2016","unstructured":"Maurer MJ, Bachy E, Ghesqui\u00e8res H, Ansell SM, Nowakowski GS, Thompson CA, Inwards DJ, Allmer C, Chassagne-Cl\u00e9ment C, Nicolas-Virelizier E, Sebban C, Lebras L, Sarkozy C, Macon WR, Feldman AL, Syrbu SI, Traverse-Glehan A, Coiffier B, Slager SL, Weiner GJ, Witzig TE, Habermann TM, Salles G, Cerhan JR, Link BK (2016) Early event status informs subsequent outcome in newly diagnosed follicular lymphoma: early events in FL. American Journal of Hematology nov 91(11):1096\u20131101","journal-title":"American Journal of Hematology nov"},{"issue":"1","key":"4025_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/asheducation-2015.1.625","volume":"2015","author":"S Montoto","year":"2015","unstructured":"Montoto S (2015) Treatment of patients with transformed lymphoma. Hematology 2015(1):625\u2013630","journal-title":"Hematology"},{"issue":"Suppl 1","key":"4025_CR18","first-page":"412","volume":"130","author":"C Casulo","year":"2017","unstructured":"Casulo C, Le-Rademacher J, Dixon J, Salles G, Hoster E, Herold M et al (2017) Validation of POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma: results from the follicular lymphoma analysis of surrogacy hypothesis (FLASH) investigation using individual data from 5,453 patients on 13 clinical trials. Blood 130(Suppl 1):412","journal-title":"Blood"},{"issue":"8","key":"4025_CR19","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1182\/blood-2016-05-717355","volume":"128","author":"V Jurinovic","year":"2016","unstructured":"Jurinovic V, Kridel R, Staiger AM, Szczepanowski M, Horn H, Dreyling MH et al (2016) Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. Blood 128(8):1112\u20131120","journal-title":"Blood"},{"issue":"4","key":"4025_CR20","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1470-2045(18)30102-5","volume":"19","author":"S Huet","year":"2018","unstructured":"Huet S, Tesson B, Jais J-P, Feldman AL, Magnano L, Thomas E, Traverse-Glehen A, Albaud B, Carr\u00e8re M, Xerri L, Ansell SM, Baseggio L, Reyes C, Tarte K, Boyault S, Haioun C, Link BK, Feugier P, Lopez-Guillermo A, Tilly H, Brice P, Hayette S, Jardin F, Offner F, Sujobert P, Gentien D, Viari A, Campo E, Cerhan JR, Salles G (2018) A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma: a retrospective training and validation analysis in three international cohorts. Lancet Oncol 19(4):549\u2013561","journal-title":"Lancet Oncol"},{"issue":"7","key":"4025_CR21","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1182\/bloodadvances.2017015164","volume":"2","author":"M-H Delfau-Larue","year":"2018","unstructured":"Delfau-Larue M-H, van der Gucht A, Dupuis J, Jais J-P, Nel I, Beldi-Ferchiou A et al (2018) Total metabolic tumor volume, circulating tumor cells, cell-free DNA: distinct prognostic value in follicular lymphoma. Blood Adv 2(7):807\u2013816","journal-title":"Blood Adv"},{"issue":"1","key":"4025_CR22","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/S2352-3026(14)70008-0","volume":"1","author":"J Trotman","year":"2014","unstructured":"Trotman J, Luminari S, Boussetta S, Versari A, Dupuis J, Tychyj C, Marcheselli L, Berriolo-Riedinger A, Franceschetto A, Julian A, Ricard F, Guerra L, Haioun C, Biasoli I, Tilly H, Federico M, Salles G, Meignan M (2014) Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies. Lancet Haematol 1(1):e17\u2013e27","journal-title":"Lancet Haematol"},{"issue":"30","key":"4025_CR23","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1200\/JCO.2016.66.9440","volume":"34","author":"M Meignan","year":"2016","unstructured":"Meignan M, Cottereau AS, Versari A, Chartier L, Dupuis J, Boussetta S et al (2016) Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: a pooled analysis of three multicenter studies. J Clin Oncol 34(30):3618\u20133626","journal-title":"J Clin Oncol"},{"issue":"6","key":"4025_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1016\/j.bbmt.2018.03.022","volume":"24","author":"V Jurinovic","year":"2018","unstructured":"Jurinovic V, Metzner B, Pfreundschuh M, Schmitz N, Wandt H, Keller U, Dreger P, Dreyling M, Hiddemann W, Unterhalt M, Hoster E, Weigert O (2018) Autologous stem cell transplantation for patients with early progression of follicular lymphoma: a follow-up study of 2 randomized trials from the German low grade lymphoma study group. Biol Blood Marrow Transplant 24(6):1172\u20131179","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"4025_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.bbmt.2017.12.771","volume":"24","author":"C Casulo","year":"2018","unstructured":"Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, Fenske TS, Freytes C, Gaballa S, Ganguly S, Jethava Y, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Solh M, Sureda A, William B, Cumpston A, Zelenetz AD, Link BK, Hamadani M (2018) Autologous transplantation in follicular lymphoma with early therapy failure: a National LymphoCare study and Center for International Blood and Marrow Transplant Research Analysis. Biol Blood Marrow Transplant 24(6):1163\u20131171","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"4025_CR26","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3324\/haematol.2010.030320","volume":"96","author":"S Le Gouill","year":"2011","unstructured":"Le Gouill S, De Guibert S, Planche L, Brice P, Dupuis J, Cartron G et al (2011) Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA\/GOELAMS FL2000 study. Haematologica 96(8):1128\u20131135","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-020-04025-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-020-04025-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T23:12:50Z","timestamp":1621120370000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-020-04025-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,16]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4025"],"URL":"https:\/\/doi.org\/10.1007\/s00277-020-04025-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,16]]},"assertion":[{"value":"26 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}